荔枝视频

Feb. 11, 2026

U荔枝视频 study investigates the use of common vitamin to treat the aggressive brain cancer glioblastoma

Findings indicate vitamin B3 looks promising to help rearm a compromised immune system
Three people wearing white lab coats smile in a lab
From left: Edward (Ed) Waldner, Gloria Roldan Urgoiti, Wee Yong Riley Brandt, 荔枝视频

Edward (Ed) Waldner had no idea why he didn鈥檛 feel well, but he knew he didn鈥檛 feel like himself. At 55 years of age, he felt exhausted all the time. It didn鈥檛 seem to matter how hard he had worked that day. He wondered if he had sleep apnea. He noticed his walking was off. His heels would drag now and again. One day, when his symptoms were worse than usual, he decided to go to the Emergency department. 

鈥淭he doctor said I had a mass on my brain and needed to see an oncologist,鈥 says Waldner. 

The mass was glioblastoma, a deadly brain cancer. Treatment often involves a three-pronged approach: surgery to remove as much of the tumour as possible, followed by radiation and chemotherapy. However, despite advances in cancer treatment, the aggressive cancer comes back. 

荔枝视频 researchers are investigating whether adding high doses of vitamin B3 or niacin to the treatment plan could be beneficial. They approached Waldner about being in the trial.

Two black and white images of a cluster of cells and then no cluster

The clustering of cancer cells in glioblastoma without treatment, left, and how the niacin stops cells from clustering.

Courtesy Yong lab

鈥淚 have no problem trying to help anybody. I agreed. I want to help myself, too,鈥 says Waldner. 鈥淚 can tell you being part of this research helps me mentally because we鈥檙e trying. When I left the hospital after surgery I was told, that鈥檚 it, that鈥檚 all we can do.鈥

Hotchkiss, Charbonneau members partner for study

The research is led by two members of both the and 鈥 , MD, PGME'16, an oncologist specialized in brain cancers, and , PhD, a neuroscientist whose research focuses on immune effects on the brain. Together, they designed a study to investigate whether niacin could rejuvenate compromised immune cells to kill tumour cells. The research began in the Yong lab, with mice, where findings showed niacin prolonged survival. That work evolved into a Phase I and II clinical trial.

Two brain scans side by side

Unrestricted tumour growth in mouse brain, left, compared to the tumour growth in a mouse who received niacin treatment, right (both after 42 days).

Courtesy Yong lab

鈥淣ormally, the immune system will try to counter and prevent tumour growth; however, this brain cancer supresses the immune system,鈥 says Yong, a professor at the (CSM). 鈥淣iacin treatment rejuvenates immune cells so they can do what they are supposed to do, attack and kill the cancer cells. I see it as an ongoing 鈥榖attle for the brain.鈥欌

Studying the benefits of adding niacin to chemotherapy, radiation

The clinical trial was designed to determine the maximum dose and potential benefit of controlled-release niacin that could be added to the recommended chemotherapy and radiotherapy treatments. Researchers decided the study would stop if the progression-free survival over six-months did not improve by at least 20 per cent compared with older studies. Early results involving 24 patients showed 82 per cent of the participants were free of progression of the cancer at six months; an increase of 28 per cent from previous studies. The researchers say this is a promising advancement for this incurable cancer. 

鈥淕lioblastoma is the most aggressive brain cancer in adults. Survival of patients with this condition hasn鈥檛 changed significantly for 20 years,鈥 says Roldan Urgoiti, a clinical associate professor at the CSM. 鈥淎nything that may help should be explored, but it requires strict protocols and safety monitoring.鈥

A man in a white lab coat points at a computer

Wee Yong

Riley Brandt, 荔枝视频

in the Journal of Neuro-Oncology.

The researchers caution that high amounts of vitamins, like niacin, have toxicity and can have a negative impact on someone鈥檚 health if not monitored closely by medical professionals. 

The team hopes to be able to do the final analysis, that will include 48 participants by the end of 2026 or early 2027. 

Waldner says he鈥檚 feeling really good these days and is just happy to hear the word "stable" when he goes for his regular scans. 

The research is supported by the and the . 

Gloria Roldan Urgoiti is a clinical associate professor in the Department of Oncology at the and a member of the , the  and the .

Wee Yong is a professor in the departments of Clinical Neurosciences and Oncology at the CSM and alsoa member of the Arnie Charbonneau Cancer Institute and the Hotchkiss Brain Institute. He holds the Canada Research Chair in Neuroimmunology.


Sign up for UToday

Sign up for UToday

Delivered to your inbox 鈥 a daily roundup of news and events from across the 荔枝视频's 14 faculties and dozens of units

Thank you for your submission.